Everolimus News and Research

RSS

New MSK-led studies on liquid biopsy presented at San Antonio Breast Cancer Symposium

Information gleaned from a liquid biopsy may help predict how individual women with advanced breast cancer will respond to certain therapies as well as reveal genetic mutations that can impact prognosis, according to two new studies led by Memorial Sloan Kettering Cancer Center Physician-in-Chief José Baselga and physician-scientist Sarat Chandarlapaty.

12 Dec 2015

Opdivo (nivolumab) approved to treat patients with advanced renal cell carcinoma

The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) renal cell carcinoma, a form of kidney cancer, who have received a certain type of prior therapy.

23 Nov 2015

Hutchison MediPharma begins sulfatinib Phase I trial in US

Hutchison China MediTech Limited today announces that Hutchison MediPharma Limited ("HMP"), its drug R&D subsidiary, has initiated the Phase I clinical trial of sulfatinib (HMPL-012) in the United States.

6 Nov 2015

Study demonstrates efficacy of everolimus in treating nonfunctional neuroendocrine tumours of the lung

The results of the international, multicenter, Phase 3 RADIANT-4 study clearly demonstrate the efficacy of the agent everolimus in treating nonfunctional neuroendocrine tumours of lung or gastrointestinal origin.

28 Oct 2015

Early trial results in lung cancer

Results from early phase trials investigating different therapeutic agents in lung cancer patients were presented during the third Presidential Session at the European Cancer Congress in Vienna, Austria. Here we summarise two studies reported at the session.

22 Oct 2015

Everolimus, 177Lu-dotatate extend neuroendocrine tumour PFS

Positive progression-free survival results from the RADIANT-4 and NETTER-1 trials extend the armamentarium for physicians treating patients with neuroendocrine tumours.

7 Oct 2015

Cabozantinib, nivolumab ‘bring hope’ for advanced RCC patients

Clinical trial results suggest significant benefits with the use of cabozantinib or nivolumab over everolimus for patients with advanced renal cell carcinoma, researchers reported at the European Cancer Congress in Vienna, Austria.

6 Oct 2015

New drug works better than current treatments for advanced kidney cancer

A new drug has been found superior to current treatments in slowing the growth of advanced kidney cancer in patients who became resistant to the first-line therapies that had kept it in check, according to results from a clinical trial led by Dana-Farber Cancer Institute.

29 Sep 2015

Nivolumab drug significantly prolongs survival in advanced kidney cancer patients

The targeted drug nivolumab significantly prolongs survival in patients with advanced kidney cancer, whose disease has progressed after their first treatment, according to results to be presented at the 2015 European Cancer Congress today (Saturday) and published simultaneously in the New England Journal of Medicine.

26 Sep 2015

Patients with advanced kidney cancer benefit from cabozantinib treatment

Patients with advanced kidney cancer live for nearly twice as long without their disease progressing if they are treated with cabozantinib, a drug that inhibits the action of tyrosine kinases - enzymes that function as an "on" or "off" switch in many cellular processes, including cancer.

26 Sep 2015

Immune checkpoint inhibitor increases survival in patients with advanced renal cell carcinoma

For the first time, an immune checkpoint inhibitor has been proven to increase survival among patients with advanced renal cell carcinoma (RCC), a patient population for whom treatment options are currently limited.

26 Sep 2015

Drug combination delivers effective punch against one form of pancreatic cancer

One form of pancreatic cancer has a new enemy: a two-drug combination discovered by UF Health researchers that inhibits tumors and kills cancer cells in mouse models.

22 Sep 2015

Bioresorbable vascular scaffold shows similar safety, efficacy results compared to metal stent

A drug-eluting coronary stent, or "scaffold" made from bioresorbable material, showed similar efficacy and safety results compared to a metal stent in patients undergoing percutaneous coronary intervention (PCI), according to results of the ABSORB Japan study.

1 Sep 2015

PRESTIGE study suggests novel target to prevent stent thrombosis

Recruitment of leukocytes is a hallmark of stent thrombosis, according to results from the PRESTIGE study presented today at ESC Congress and published in European Heart Journal. The findings suggest that immune cell mediated thrombotic processes may be a realistic target for novel therapies to prevent stent thrombosis.

1 Sep 2015

STEMI study: Absorbable stents perform similarly to metallic stents

A drug-eluting coronary stent made of absorbable material performed similarly to the gold-standard metal one in a non-inferiority trial among patients with the more serious type of heart attack known as ST-segment elevation myocardial infarction (STEMI), according to results of the ABSORB STEMI TROFI II trial.

1 Sep 2015

Abbott reports positive results of ABSORB Japan study comparing efficacy of fully dissolving heart stent to XIENCE

Abbott (NYSE: ABT) announced today positive one-year clinical results from ABSORB Japan, a multi-center, randomized trial comparing the safety and effectiveness of Abbott's fully dissolving Absorb™ heart stent to XIENCE ®, Abbott's market-leading, permanent drug eluting stent.

1 Sep 2015

Prasugrel linked to high-bleeding-risk in patients with stable coronary artery disease

Prasugrel-based dual antiplatelet therapy is associated with increased major bleeding after stent implantation for high-risk patients with stable coronary artery disease, according to a secondary analysis of the BASKET-PROVE II trial presented at ESC Congress for the first time today.

1 Sep 2015

ESC Congress to highlight results from global trials in six press conferences

Members of the press will be the first to hear the highly anticipated results from global trials in six press conferences devoted to hot lines research.

13 Aug 2015

Boston Scientific commences new study to evaluate fully resorbable drug-eluting scaffold system

Boston Scientific has initiated a study of the company's first fully resorbable drug-eluting scaffold system. The Fully Absorbable Scaffold Feasibility Study (FAST) is a prospective, single arm study designed to assess the safety and performance of this next generation scaffold for the treatment of atherosclerotic coronary lesions.

21 Jul 2015

Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

Eisai Inc. announced today results from an investigational Phase 2 trial which showed that lenvatinib, when used in combination with everolimus, significantly extended progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC) versus everolimus alone.

1 Jun 2015

Everolimus News and Research

New MSK-led studies on liquid biopsy presented at San Antonio Breast Cancer Symposium

Opdivo (nivolumab) approved to treat patients with advanced renal cell carcinoma

Hutchison MediPharma begins sulfatinib Phase I trial in US

Study demonstrates efficacy of everolimus in treating nonfunctional neuroendocrine tumours of the lung

Early trial results in lung cancer

Everolimus, 177Lu-dotatate extend neuroendocrine tumour PFS

Cabozantinib, nivolumab ‘bring hope’ for advanced RCC patients

New drug works better than current treatments for advanced kidney cancer

Nivolumab drug significantly prolongs survival in advanced kidney cancer patients

Patients with advanced kidney cancer benefit from cabozantinib treatment

Immune checkpoint inhibitor increases survival in patients with advanced renal cell carcinoma

Drug combination delivers effective punch against one form of pancreatic cancer

Bioresorbable vascular scaffold shows similar safety, efficacy results compared to metal stent

PRESTIGE study suggests novel target to prevent stent thrombosis

STEMI study: Absorbable stents perform similarly to metallic stents

Abbott reports positive results of ABSORB Japan study comparing efficacy of fully dissolving heart stent to XIENCE

Prasugrel linked to high-bleeding-risk in patients with stable coronary artery disease

ESC Congress to highlight results from global trials in six press conferences

Boston Scientific commences new study to evaluate fully resorbable drug-eluting scaffold system

Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News